Merck has developed a cure for COVID 19 Molnupiravir Molnupiravir
Pharmaceutical company Merck reported, that has developed an effective cure for COVID-19 (Molnupiravir Molnupiravir). Shares of Merck and most airlines soared, while vaccine developer Moderna's papers fell by 11,4%. Merck and Ridgeback's research oral antiviral drug Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared to placebo for patients with mild to moderate COVID-19 in a positive interim analysis of a phase study 3